Advertisement
U.S. markets open in 46 minutes

Helix BioPharma Corp. (HBP.TO)

Toronto - Toronto Real Time Price. Currency in CAD
0.18000.0000 (0.00%)
At close: 01:44PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1800
Open0.1800
Bid0.1700 x 0
Ask0.2000 x 0
Day's Range0.1800 - 0.1800
52 Week Range0.1500 - 0.2600
Volume14,017
Avg. Volume12,482
Market Cap39.001M
Beta (5Y Monthly)-0.71
PE Ratio (TTM)N/A
EPS (TTM)-0.0300
Earnings DateMar 28, 2024 - Apr 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for HBP.TO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • News Direct

      Helix BioPharma Corp. Reports Voting Results

      January 18, 2024 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field o...

    • News Direct

      Helix BioPharma Corp. Announces Fiscal 2024 First Quarter Results

      Toronto, Ontario – TheNewswire – December 14, 2023 – Helix BioPharma Corp. (TSX:HBP), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field...

    • NewMediaWire

      Helix BioPharma Corp. Announces Fiscal 2023 Year-End Results

      TORONTO - (NewMediaWire) - October 27, 2023 - TheNewswire - Helix BioPharma Corp. (TSX:HBP), ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary t...